Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
ACELYRIN, INC. Common Stock (SLRN)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: SLRN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -74.77% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 215.70M USD | Price to earnings Ratio - | 1Y Target Price 9.17 |
Price to earnings Ratio - | 1Y Target Price 9.17 | ||
Volume (30-day avg) 1350203 | Beta - | 52 Weeks Range 1.91 - 8.88 | Updated Date 01/14/2025 |
52 Weeks Range 1.91 - 8.88 | Updated Date 01/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.46 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.89% | Return on Equity (TTM) -41.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -340115027 | Price to Sales(TTM) - |
Enterprise Value -340115027 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.46 | Shares Outstanding 100326000 | Shares Floating 64322149 |
Shares Outstanding 100326000 | Shares Floating 64322149 | ||
Percent Insiders 8.03 | Percent Institutions 99.44 |
AI Summary
ACELYRIN, INC. Common Stock: A Comprehensive Overview
Company Profile:
ACELYRIN, INC. (NASDAQ: ACRY) is a clinical-stage pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of pulmonary diseases. Founded in 2010, the company leverages its proprietary Pulmonary Kinetic Delivery System (PKDS) platform to deliver targeted therapies directly to the lungs.
Leadership and Structure:
ACELYRIN's leadership team includes experienced individuals from the pharmaceutical and biotechnology industries. The company operates through a Board of Directors responsible for strategic guidance and oversight.
Top Products and Market Share:
ACELYRIN currently does not have any marketed products. Their lead product candidate, Saphnelo™, is in Phase 3 clinical development for the treatment of chronic obstructive pulmonary disease (COPD), a large and growing market with unmet medical needs. The company also has other early-stage product candidates in the pipeline.
Total Addressable Market:
The global market for COPD therapies is estimated to reach $8.6 billion by 2025, with the US market accounting for a significant share.
Financial Performance:
ACELYRIN, being a pre-commercial clinical-stage company, currently does not generate revenue. It reports operating losses due to research and development activities. The company has funded its operations through equity financing and grants.
Dividends and Shareholder Returns:
As a pre-revenue company, ACELYRIN does not currently pay dividends. Shareholder returns will depend on the success of its clinical pipeline and future commercialization efforts.
Growth Trajectory:
ACELYRIN's growth prospects are directly tied to the success of its clinical pipeline, particularly Saphnelo™ for COPD.
Market Dynamics:
The COPD treatment market is highly competitive, with established players such as GlaxoSmithKline (GSK) and Boehringer Ingelheim dominating. ACELYRIN's success hinges on its ability to differentiate its product portfolio and capture market share.
Competitors:
Key competitors include GlaxoSmithKline (GSK), Boehringer Ingelheim, Sunovion Pharmaceuticals (SONV), and AstraZeneca (AZN).
Recent Acquisitions:
ACELYRIN has not had any acquisitions in the past three years.
AI-Based Fundamental Rating:
Given its pre-revenue stage and the inherent risks associated with drug development, an AI-based fundamental rating would likely assign a moderate score to ACELYRIN, reflecting the potential for growth but also the challenges it faces. The company's success in clinical trials and subsequent commercialization efforts will significantly impact its future prospects.
Sources and Disclaimers:
This overview utilized information from ACELYRIN's website, U.S. Securities and Exchange Commission filings, and relevant industry reports. Investment decisions should consider all relevant information and consult with qualified financial professionals.
Disclaimer: This information is provided for informational purposes only and should not be considered investment advice. Please consult with a professional financial advisor before making any investment decisions.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Agoura Hills, CA, United States | ||
IPO Launch date 2023-05-04 | CEO & Director Ms. Mina Kim J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 135 | Website https://www.acelyrin.com |
Full time employees 135 | Website https://www.acelyrin.com | ||
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.